GlassScriptPhysician profile
Thanyapatt Han
NPI 1255096285
$687.91
in general payments reported to CMS, 2019-2025
11 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $167 · 2023: $264 · 2024: $58.38 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $83.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.49 |
| Education | $83.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $103.93 | 2025 | Clonoseq |
| Janssen Biotech, INC. | $90.72 | 2023 | Darzalex, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $90.51 | 2024-2025 | Ninlaro |
| Sanofi-Aventis U.S. LLC | $83.00 | 2023 | |
| Pfizer INC. | $62.26 | 2025 | |
| Celgene Corporation | $47.56 | 2023 | Pomalyst |
| Genzyme Corporation | $25.38 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.75 | 2022 | |
| Daiichi Sankyo INC. | $20.67 | 2022 | |
| Amgen INC. | $17.13 | 2023 | Xgeva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanyapatt Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.